At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 416 enrolled
Drug / intervention
Experimental: Tezepelumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT)
In Brief
A Phase 3 clinical trial evaluating Experimental: Tezepelumab, Placebo, and 1 other intervention for Chronic Rhinosinusitis With Nasal Polyps. Completed, enrolled 416 participants across 112 sites in 10 countries.
Detailed Summary
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Rhinosinusitis With Nasal Polyps
CountriesCanada, China, Denmark, Germany, Hungary, Japan, Poland, Spain, United Kingdom, United States
CollaboratorsAmgen
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartApr 2021
Primary CompletionSep 2024
Study CompletionDec 2024
TodayJul 2026
First PostedApr 21, 2021
Enrollment StartApr 22, 2021
Primary CompletionSep 23, 2024
Study CompletionDec 11, 2024
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 5.2 years ago
Interventions
Experimental: Tezepelumabbiological
Tezepelumab subcutaneous injection
Placeboother
Placebo subcutaneous injection
Mometasone furoate or equivalent intranasal corticosteroiddrug
Background MFNS or equivalent INCS at stable dose